For instance, Raf inhibitors such as vemurafenib are effective in the treatment of BRAF mutant melanoma; however, BRAF mutant colorectal cancer is resistant to vemurafenib due to feedback up-regulation of ERK signaling (92, 93). This evidence concerns the gene BRAF and colorectal cancer.